Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPA vs DHA for Major Depressive Disorder
NCT00361374Phase 3Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2006
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing EPA Group, DHA Group and Placebo Group (3 arms). Primary endpoint: Score on a Depression Severity Rating Scale at 8 weeks. Started Jul 2006; status: completed.
02
Drugs
eicosapentaenoic aciddocosahexaenoic acid
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00361374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00361374.